Entrada Therapeutics, INC 8-K filings

Entrada Therapeutics announced its second quarter 2026 financial results, highlighting progress in its Duchenne muscular dystrophy (DMD) programs and outlining a schedule for key clinical data readouts.

Entrada Therapeutics announced that its stockholders approved amendments to its 2021 Stock Option and Incentive Plan and 2021 Employee Stock Purchase Plan at the 2026 Annual Meeting.

Entrada Therapeutics announced positive topline results from Cohort 1 of its Phase 1/2 ELEVATE-44-201 study for Duchenne Muscular Dystrophy, alongside Q1 2026 financial results and an updated cash runway.

Entrada Therapeutics announced its fourth quarter and full year 2025 financial results, alongside significant clinical progress in its Duchenne muscular dystrophy (DMD) and inherited retinal disease programs.

Entrada Therapeutics reported significant progress across its RNA-based therapeutic portfolio for neuromuscular and ocular diseases, including Duchenne muscular dystrophy programs and a new candidate for Usher syndrome, while maintaining a cash runway into Q3 2027.

Entrada Therapeutics reported Q3 2025 financial results, highlighted significant progress in its Duchenne muscular dystrophy clinical programs, and extended its cash runway into Q3 2027.

Entrada Therapeutics announced its Q2 2025 financial results, highlighted significant clinical advancements in its Duchenne muscular dystrophy programs, and expanded its leadership team.

Entrada Therapeutics, Inc. announced the successful approval of all matters presented at its 2025 Annual Meeting of Stockholders, including the re-election of three Class I directors and the ratification of Ernst & Young LLP as its independent registered public accounting firm.

Entrada Therapeutics, a clinical-stage biopharmaceutical company, announced the expansion of its Board of Directors and the appointment of Dr. Maha Radhakrishnan, a seasoned biopharmaceutical executive, effective June 1, 2025.

Entrada Therapeutics announces Q1 2025 financial results, highlights EU regulatory authorization for a Duchenne muscular dystrophy clinical study, and maintains a cash runway into Q2 2027.

Entrada Therapeutics is implementing a strategic plan involving workforce reductions to prioritize its Duchenne muscular dystrophy (DMD) and ocular programs.

Entrada Therapeutics has been authorized in the UK to begin a Phase 1/2 clinical study of ENTR-601-45 for Duchenne Muscular Dystrophy (DMD) amenable to exon 45 skipping.

Entrada Therapeutics announces positive financial results for Q4 and full year 2024, highlighting progress in Duchenne muscular dystrophy (DMD) programs and a strong cash position extending into Q2 2027.

The FDA has removed the clinical hold on Entrada Therapeutics' ENTR-601-44, allowing the company to proceed with a Phase 1b clinical study for Duchenne muscular dystrophy (DMD).

Entrada Therapeutics has received authorization in the UK to begin a Phase 1/2 clinical trial for its drug ENTR-601-44, aimed at treating Duchenne muscular dystrophy.

Entrada Therapeutics reports approximately $420 million in cash resources as of December 31, 2024, projecting runway into the second quarter of 2027, and provides updates on its clinical pipeline at the J.P. Morgan Healthcare Conference.

Entrada Therapeutics announced its Q3 2024 financial results, highlighting advancements in its Duchenne muscular dystrophy programs and a strong cash runway extending into 2027.

Entrada Therapeutics reported positive Phase 1 clinical trial results for its DMD program and completed a $100 million financing, extending its cash runway into 2027.

Entrada Therapeutics has successfully raised approximately $100 million through a registered direct offering of common stock and pre-funded warrants.

Entrada Therapeutics reported positive preliminary results from its Phase 1 trial of ENTR-601-44, a potential treatment for Duchenne muscular dystrophy, showing good safety and target engagement.

Entrada Therapeutics held its 2024 Annual Meeting, approving an amendment to its charter to limit officer liability and electing a new Class III director.

Entrada Therapeutics announced positive first quarter 2024 financial results, highlighted by a $75 million milestone payment from Vertex and advancements in their clinical programs.

Entrada Therapeutics announced its 2023 financial results, highlighting a strong cash position and advancements in its clinical programs, particularly for Duchenne muscular dystrophy.